Feasibility of Generating Adeno-Associated Virus Packaging Cell Lines Containing Inducible Adenovirus Helper Genes
- 15 February 2002
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 76 (4), 1904-1913
- https://doi.org/10.1128/jvi.76.4.1904-1913.2002
Abstract
The adeno-associated virus (AAV) vector system is based on nonpathogenic and helper-virus-dependent parvoviruses. The vector system offers safe, efficient, and long-term in vivo gene transfer in numerous tissues. Clinical trials using AAV vectors have demonstrated vector safety as well as efficiency. The increasing interest in the use of AAV for clinical studies demands large quantities of vectors and hence a need for improvement in vector production. The commonly used transient-transfection method, although versatile and free of adenovirus (Ad), is not cost-effective for large-scale production. While the wild-type-Ad-dependent AAV producer cell lines seem to be cost-effective, this method faces the problem of wild-type Ad contamination. To overcome these shortcomings, we have explored the feasibility of creating inducible AAV packaging cell lines that require neither transfection nor helper virus infection. As a first step toward that goal, we have created a cell line containing highly inducible Ad E1A and E1B genes, which are essential for AAV production. Subsequently, the AAV Rep and Cap genes and an AAV vector containing a green fluorescent protein (GFP) reporter gene were stably introduced into the E1A-E1B cell line, generating inducible AAV-GFP packaging cell lines. Upon induction of E1A and E1B genes and infection with replication-defective Ad with E1A, E1B, and E3 deleted, the packaging cells yielded high-titer AAV-GFP vectors. Finally, the E2, E4, and VA genes of Ad, under the control of their endogenous promoters, were also introduced into these cells. A few producer cell lines were obtained, which could produce AAV-GFP vectors upon simple drug induction. Although future improvement is necessary to increase the stability and vector yield of the cells, our study has nonetheless demonstrated the feasibility of generating helper-virus-free inducible AAV producer cell lines.Keywords
This publication has 58 references indexed in Scilit:
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in LiverMolecular Therapy, 2000
- A Cell Line for High-Yield Production of E1-Deleted Adenovirus Vectors without the Emergence of Replication-Competent VirusHuman Gene Therapy, 2000
- Progress in Adeno-Associated Virus Type 2 Vector Production: Promises and Prospects for Clinical UseHuman Gene Therapy, 1999
- Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirusGene Therapy, 1999
- High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle VirusHuman Gene Therapy, 1998
- Factors Influencing Recombinant Adeno-Associated Virus ProductionHuman Gene Therapy, 1998
- Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophiliaGene Therapy, 1998
- Cell Lines for the Production of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1995
- Adeno-associated virus (AAV) vectors for gene transferAdvanced Drug Delivery Reviews, 1993